Last updated on July 2019

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON


Brief description of study

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 300 patients will be enrolled.

Detailed Study Description

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD.

Patients will be randomized 1:1 to either bardoxolone methyl or placebo. Patients receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Dose de-escalation is permitted during the study if indicated clinically, and subsequent dose re-escalation is also permitted to meet the dosing objective of the highest tolerated dose.

All patients in the study will follow the same visit and assessment schedule. Following randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 and by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100. Patients will also be scheduled to be assessed at an in-person follow-up visit at Week 104, four weeks after the end of treatment.

Clinical Study Identifier: NCT03918447

Find a site near you

Start Over

Volunteer Medical Research

Port Charlotte, FL United States
  Connect »

Northwest Louisiana Nephrology

Shreveport, LA United States
  Connect »

Research Management, Inc.

Austin, TX United States
  Connect »

Clinical Advancement Center

San Antonio, TX United States
  Connect »

Nephrology Consultants, LLC

Huntsville, AL United States
  Connect »

AKDHC

Glendale, AZ United States
  Connect »

Aventiv Research, Inc

Mesa, AZ United States
  Connect »

University of Arizona

Tucson, AZ United States
  Connect »

Apex Research of Riverside

Riverside, CA United States
  Connect »

Western Nephrology

Arvada, CO United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Renal Associates of Baton Rouge

Baton Rouge, LA United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

Michigan Kidney Consultants

Pontiac, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Nephrology Associates, P.C.

Flushing, NY United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Nephrology Associates, P.C.

Nashville, TN United States
  Connect »

DaVita Med Center

Houston, TX United States
  Connect »

University of Virginia

Charlottesville, VA United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Renal Research

Gosford, Australia
  Connect »

John Hunter Hospital

New Lambton, Australia
  Connect »

Monash Health

Clayton, Australia
  Connect »

Epworth HealthCare

Hawthorn, Australia
  Connect »

Melbourne Health

Parkville, Australia
  Connect »

FN Brno

Brno, Czechia
  Connect »

IKEM

Praha, Czechia
  Connect »

Royal Free Hospital

London, United Kingdom
  Connect »